ATE396723T1 - Verwendung von urocansäure zur ansäuerung des zellzytoplasmas und zur prävention oder zum aufhalten der zellproliferation in einer person - Google Patents

Verwendung von urocansäure zur ansäuerung des zellzytoplasmas und zur prävention oder zum aufhalten der zellproliferation in einer person

Info

Publication number
ATE396723T1
ATE396723T1 AT04798326T AT04798326T ATE396723T1 AT E396723 T1 ATE396723 T1 AT E396723T1 AT 04798326 T AT04798326 T AT 04798326T AT 04798326 T AT04798326 T AT 04798326T AT E396723 T1 ATE396723 T1 AT E396723T1
Authority
AT
Austria
Prior art keywords
person
acidify
urocanic acid
prevent
cell proliferation
Prior art date
Application number
AT04798326T
Other languages
English (en)
Inventor
Lasse Leino
Jarmo Laihia
Original Assignee
Biocis Pharma Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29763491&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE396723(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biocis Pharma Oy filed Critical Biocis Pharma Oy
Application granted granted Critical
Publication of ATE396723T1 publication Critical patent/ATE396723T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT04798326T 2003-12-09 2004-11-26 Verwendung von urocansäure zur ansäuerung des zellzytoplasmas und zur prävention oder zum aufhalten der zellproliferation in einer person ATE396723T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FI20031793A FI20031793A0 (fi) 2003-12-09 2003-12-09 Uusi anti-proliferatiivinen farmaseuttinen koostumus

Publications (1)

Publication Number Publication Date
ATE396723T1 true ATE396723T1 (de) 2008-06-15

Family

ID=29763491

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04798326T ATE396723T1 (de) 2003-12-09 2004-11-26 Verwendung von urocansäure zur ansäuerung des zellzytoplasmas und zur prävention oder zum aufhalten der zellproliferation in einer person

Country Status (17)

Country Link
US (2) US20060189691A1 (de)
EP (1) EP1691805B1 (de)
JP (1) JP4825680B2 (de)
CN (1) CN1889950B (de)
AT (1) ATE396723T1 (de)
AU (1) AU2004296570B2 (de)
CA (1) CA2544720C (de)
CY (1) CY1108163T1 (de)
DE (1) DE602004014187D1 (de)
DK (1) DK1691805T3 (de)
ES (1) ES2303113T3 (de)
FI (1) FI20031793A0 (de)
PL (1) PL1691805T3 (de)
PT (1) PT1691805E (de)
SI (1) SI1691805T1 (de)
WO (1) WO2005056007A1 (de)
ZA (1) ZA200602940B (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI20030379A0 (fi) * 2003-03-14 2003-03-14 Lasse Leino Uusi farmaseuttinen koostumus

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4121030A1 (de) * 1990-06-29 1992-01-02 Beiersdorf Ag Dermatologische zusammensetzungen mit einem gehalt an cis-urocaninsaeure
US5455036A (en) * 1990-06-29 1995-10-03 Bode Chemie Method of using cis-urocaninic acid for topically treating psoriasis
DE4122497C2 (de) 1991-07-02 1998-03-26 Wogepharm Gmbh Verwendung von trans-Urokaninsäure bei der prophylaktischen Therapie der Psoriasis
US5843979A (en) 1993-02-25 1998-12-01 Bristol-Myers Squibb Company Transdermal treatment with mast cell degranulating agents for drug-induced hypersensitivity
CA2114968A1 (en) * 1993-02-25 1994-08-26 John Wille Transdermal treatment with mast cell degranulating agents for drug-induced hypersensitivity
GB9306473D0 (en) * 1993-03-29 1993-05-19 Bioglan Lab Ltd Pharmaceutically useful compounds
US5686100A (en) * 1994-11-22 1997-11-11 E.R. Squibb & Sons, Inc. Prophylactic and therapeutic treatment of skin sensitization and irritation
US5576013A (en) * 1995-03-21 1996-11-19 Eastern Virginia Medical School Treating vascular and neoplastic tissues
AU3309097A (en) * 1996-06-12 1998-01-07 Alza Corporation Reduction of skin sensitization in electrotransport drug delivery
DE19638064C2 (de) * 1996-09-18 1998-08-20 Voith Turbo Kg Verfahren zur Steuerung von Schaltvorgängen bei einem Fahrzeuggetriebe
DE19817295A1 (de) * 1998-04-18 1999-10-21 Beiersdorf Ag Kosmetische oder dermatologische Zubereitungen mit einem Gehalt an unsymmetrisch substituiertenTriazinderivaten zum Erhalt des Urocaninsäurestatus der Haut
US6420378B1 (en) * 1999-10-15 2002-07-16 Supergen, Inc. Inhibition of abnormal cell proliferation with camptothecin and combinations including the same
EP1280924A2 (de) * 2000-04-14 2003-02-05 University of South Carolina Research Foundation Klonierung einer corynebacteriaceae histidine ammonia lyase und therapeutische verwendungen
US6582734B1 (en) 2000-07-20 2003-06-24 Ecolab Inc. Antimicrobial composition useful for the treatment of bovine mastitis
US6541509B2 (en) * 2000-09-15 2003-04-01 Albert Einstein College Of Medicine Of Yeshiva University Method for treating neoplasia using combination chemotherapy
FI20030379A0 (fi) * 2003-03-14 2003-03-14 Lasse Leino Uusi farmaseuttinen koostumus

Also Published As

Publication number Publication date
FI20031793A0 (fi) 2003-12-09
WO2005056007A1 (en) 2005-06-23
AU2004296570B2 (en) 2011-01-06
DK1691805T3 (da) 2008-10-06
EP1691805A1 (de) 2006-08-23
ZA200602940B (en) 2007-07-25
CA2544720A1 (en) 2005-06-23
JP4825680B2 (ja) 2011-11-30
US20060189692A1 (en) 2006-08-24
PL1691805T3 (pl) 2008-11-28
CN1889950A (zh) 2007-01-03
ES2303113T3 (es) 2008-08-01
EP1691805B1 (de) 2008-05-28
CY1108163T1 (el) 2014-02-12
CN1889950B (zh) 2011-02-09
JP2007513927A (ja) 2007-05-31
US8338475B2 (en) 2012-12-25
US20060189691A1 (en) 2006-08-24
PT1691805E (pt) 2008-06-12
SI1691805T1 (sl) 2008-08-31
CA2544720C (en) 2012-01-03
AU2004296570A1 (en) 2005-06-23
DE602004014187D1 (de) 2008-07-10

Similar Documents

Publication Publication Date Title
CY1108932T1 (el) Ενωσεις 4-(ετεροκυκλυλ)-βενζολοσουλφοξιμινης για την θεραπευτικη αγωγη φλεγμονωδων ασθενειων
HUP0003386A2 (hu) CRF antagonisták alkalmazása depresszió, kardiovaszkuláris betegségek kezelésére szolgáló gyógyszerkészítmények előállítására
ATE320426T1 (de) Harnstoffderivate und ihre verwendung
ATE388951T1 (de) Dpp-iv-inhibierende purin-derivative zur behandlung von diabetes
MXPA05013224A (es) Piridinilcarbamatos como inhibidores de lipasa sensible a hormonas.
DK1161248T3 (da) Farmaceutisk sammensætning indeholdende en nitratkilde og et forsurende middel til behandling af åbne sår og forbrændinger
JO2373B1 (en) W-carboxy-aryl diphenyl urease substitutes used as RAV inhibitors
ATE119520T1 (de) Derivate von hydroxaminsäure und von n- hydroxyharnstoff sowie ihre verwendung.
NO20093464L (no) Nye medikamentblandinger basert pa anti-cholinergisk effektive forbindelser og beta-mimetika
NO20051966L (no) Nye pyrimidinamidderivater og anvendelse derav
SE9900961D0 (sv) Novel compounds
DE69628415D1 (de) Arzneimittel enthaltend monoaminooxidase-b-hemmer
NZ513096A (en) Compositions for treating inflammatory response
SE0401655D0 (sv) New compounds
PA8525801A1 (es) Compuestos de pirazol, composiciones farmacéuticas, y métodos para modular y/o inhibir la actividad de erab/hadh2
ATE396723T1 (de) Verwendung von urocansäure zur ansäuerung des zellzytoplasmas und zur prävention oder zum aufhalten der zellproliferation in einer person
CY1107346T1 (el) Φαρμακευτικη συνθεση για την ενδοκυτταρια οξινιση με cis-ουροκανικο οξυ
SE0301884D0 (sv) New use III
ATE428709T1 (de) Anthranilsäureamide und ihre pharmazeutische verwendung
SE9802207D0 (sv) Novel compounds
AT8429U2 (de) Herstellung einer desmopressin umfassenden zusammensetzung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1691805

Country of ref document: EP